Former Inogen CEO, Ray Huggenberger, Joins Ebb Therapeutics Board of Directors
PITTSBURGH, Sept. 18, 2018 /PRNewswire/ -- Ebb Therapeutics, a med-tech start-up that develops innovative products designed to help the millions of insomnia sufferers, announces that its added Ray Huggenberger to its Board of Directors.
During Huggenberger's nine-year tenure as the CEO of Inogen (INGN), the medical technology company that develops, manufactures and markets oxygen concentrators, it experienced extraordinary growth and cemented its category leadership position, further distancing itself from any potential competitors. Mr. Huggenberger will remain on Inogen's Board of Directors.
"Ray is the perfect executive to fill our last Board seat. His experience in successfully launching new-to-category medical technologies, via direct-to-consumer marketing, is analogous to our current business model. And his strategic insights for building the business, first in the United States, and then globally, will be invaluable," said CEO, Ebb Therapeutics Inc., Don Spence.
Prior to joining Inogen, Huggenberger held various executive leadership roles with companies including Sunrise Medical Inc., a global manufacturer of durable medical equipment, and the healthcare division of TA Triumph Adler.
Mr. Huggenberger also serves on the Board of Wellfount Corporation, a pharmacy services company, as well as Clarify Medical, a dermatology company, Sommetrics, a respiratory company and Tactile Medical (TCMD), a publicly-traded medical device company for the treatment of lymphedema.
"Insomnia and general sleeplessness have reached global crisis status, with 174+ million sufferers in America alone. And until now, the market hasn't seen a fully credible, clinically-validated and completely drug-free alternative to sleeping pills. Ebb Insomnia Therapy is a category-disrupting product, backed by ten years of evidential data that has allowed it to secure FDA clearance. I'm excited to partner with the company's executive leadership team in what will prove to be a successful, commercialization journey," said Huggenberger.
About Ebb Therapeutics
Headquartered in Pittsburgh, PA, the privately-held company was founded in 2008 by Eric Nofzinger, M.D., after he performed pioneering brain imaging studies on insomnia patients at the University of Pittsburgh. His research resulted in the development of Ebb Insomnia Therapy, a clinically-safe, medical-grade device, with none of the side effects found in traditional treatments. Ebb Therapeutics was funded in part by a grant from the National Institutes of Health, as well as private equity and venture capital firms, KKR, Arboretum Ventures, Versant Ventures and Partner Ventures.
To learn more, visit http://www.ebbsleep.com.
SOURCE Ebb Therapeutics Inc.